Idexx Laboratories, Inc. announced that it has received approval from the US Food and Drug Administration (FDA) to market and sell Navigator (32 per cent nitazoxanide) Antiprotozoal oral paste, a new treatment for equine protozoal myeloencephalitis (EPM), a progressive, degenerative disease of the central nervous system that can cause serious or even fatal neurological problems in horses.

"Navigator paste is a powerful new treatment for this potentially devastating disease," commented Idexx president and CEO Jonathan Ayers. "Navigator is a significant component of our strategy to provide innovative diagnostic and therapeutic solutions to equine veterinarians."

Idexx Laboratories, Inc., is a worldwide leader in the development and commercialization of innovative, technology-based products and services for animal health. The company's largest business is focused on companion animal health, combining biotechnology, medical device technology and information technology to aid veterinarians in providing better medicine while building successful practices.